Paper
0
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Authors
Srđan Verstovšek,Ruben Mesa
Jason Gotlib,Richard Levy,Vikas Gupta,John DiPersio,John Catalano,Michael Deininger,Carole Miller,Richard Silver,Moshe Talpaz,Elliott Winton,John Harvey,Murat Arcasoy,Elizabeth Hexner,Roger Lyons,Ronald Paquette,Azra Raza,Kris Vaddi,Susan Erickson‐Viitanen,Iphigenia Koumenis,William Sun,Victor Sandor,Hagop Kantarjian
+22 authors
,Jimmie HarveyPublished
Feb 29, 2012
Show more
Save
Tip0
TipSave
Abstract
Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.